Our gene therapy candidate for Rett syndrome, TSHA-102, is designed to help address the technical challenges presented by one of the most common genetic causes of severe intellectual disability in females.

Taysha Gene Therapies is singularly focused on discovering, developing and commercializing gene therapies for the treatment of monogenic diseases of the central nervous system (CNS), in both rare and large patient populations.

A detailed overview of Taysha Gene Therapies, Inc. (TSHA) stock, including real-time price, chart, key statistics, news, and more.

Should You Buy or Sell Taysha Gene Therapies Stock? Get The Latest TSHA Stock Analysis, Price Target, Earnings Estimates, Headlines, and Short Interest at MarketBeat.

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company, which engages in the development and commercialization of adeno-associated viruses (AAV) based gene therapies for...

Taysha Gene Therapies, Inc. announced the pricing of a public offering of 32,500,001 shares of its common stock at $6.00 per share, alongside pre-funded warrants for an additional 833,333 shares at $5.999 each. The offering aims to raise approximately $200 million in gross proceeds before fees and is expected to close by June 26, 2026.

About Taysha Gene Therapies Taysha Gene Therapies (Nasdaq: TSHA) is a clinical-stage biotechnology company focused on advancing adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system.

TSHA-102 is a self-complementary, intrathecally delivered AAV9 investigational gene transfer therapy. The one-time AAV treatment is designed to address the genetic root cause of Rett syndrome by delivering a functional copy of the MECP2 gene to CNS cells.